HFS
PTGX icon

Hantz Financial Services’s Protagonist Therapeutics PTGX Stock Holding History

Hantz Financial Services’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$123K Buy
1,007
+150
+18% +$15.7K ﹤0.01% 1319
2026
Q1 		$90K Sell
857
-94
-10% -$8.32K ﹤0.01% 1327
2025
Q4 		$83K Buy
951
+656
+222% +$53.7K ﹤0.01% 1227
2025
Q3 		$20K Buy
295
+152
+106% +$8.64K ﹤0.01% 1569
2025
Q2 		$8K Buy
143
+141
+7,050% +$6.77K ﹤0.01% 1598
2025
Q1 		$0 Buy
+2
New +$84 ﹤0.01% 1920

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Hantz Financial Services's PTGX Position: Q2 2026 in Review

Hantz Financial Services increased its Protagonist Therapeutics (PTGX) stake by 18% in Q2 2026, buying an estimated $15.7K and bringing the position to 1,007 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #1319.

Hantz Financial Services first reported a position in PTGX in Q1 2025 and has held it in 6 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Hantz Financial Services held 1,007 shares of Protagonist Therapeutics worth $123K as of Q2 2026.
  • Hantz Financial Services bought 150 Protagonist Therapeutics shares in Q2 2026, an estimated $15.7K.
  • Protagonist Therapeutics made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #1319 holding.
  • Hantz Financial Services first reported a position in Protagonist Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.